FR3037338A1 - Procede de greffe de cellule cardiaque sur la membrane choriallantoide d'œuf feconde - Google Patents
Procede de greffe de cellule cardiaque sur la membrane choriallantoide d'œuf feconde Download PDFInfo
- Publication number
- FR3037338A1 FR3037338A1 FR1555364A FR1555364A FR3037338A1 FR 3037338 A1 FR3037338 A1 FR 3037338A1 FR 1555364 A FR1555364 A FR 1555364A FR 1555364 A FR1555364 A FR 1555364A FR 3037338 A1 FR3037338 A1 FR 3037338A1
- Authority
- FR
- France
- Prior art keywords
- cell
- cardiac
- egg
- fertilized egg
- mca
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 238000000034 method Methods 0.000 title claims abstract description 91
- 210000002064 heart cell Anatomy 0.000 title claims abstract description 82
- 239000012528 membrane Substances 0.000 title description 4
- 210000005003 heart tissue Anatomy 0.000 claims abstract description 73
- 210000004027 cell Anatomy 0.000 claims abstract description 67
- 210000003711 chorioallantoic membrane Anatomy 0.000 claims abstract description 27
- 150000001875 compounds Chemical class 0.000 claims abstract description 27
- 230000000694 effects Effects 0.000 claims abstract description 27
- 239000012634 fragment Substances 0.000 claims description 42
- 238000002513 implantation Methods 0.000 claims description 18
- 238000011534 incubation Methods 0.000 claims description 15
- 238000011161 development Methods 0.000 claims description 13
- 241000287828 Gallus gallus Species 0.000 claims description 9
- 235000013330 chicken meat Nutrition 0.000 claims description 9
- 241000700159 Rattus Species 0.000 claims description 5
- 239000002250 absorbent Substances 0.000 claims description 5
- 230000002745 absorbent Effects 0.000 claims description 5
- 238000004458 analytical method Methods 0.000 claims description 5
- 239000000126 substance Substances 0.000 claims description 5
- 241000282412 Homo Species 0.000 claims description 4
- 241000699670 Mus sp. Species 0.000 claims description 4
- 238000012512 characterization method Methods 0.000 claims description 4
- 238000010253 intravenous injection Methods 0.000 claims description 4
- 210000000130 stem cell Anatomy 0.000 claims description 4
- 229920000742 Cotton Polymers 0.000 claims description 3
- 241000124008 Mammalia Species 0.000 claims description 3
- 241000282887 Suidae Species 0.000 claims description 3
- 241000251539 Vertebrata <Metazoa> Species 0.000 claims description 3
- 239000002243 precursor Substances 0.000 claims description 3
- 230000033764 rhythmic process Effects 0.000 claims description 3
- 238000007790 scraping Methods 0.000 claims description 3
- 241000271566 Aves Species 0.000 claims description 2
- 206010048610 Cardiotoxicity Diseases 0.000 claims description 2
- 241000282693 Cercopithecidae Species 0.000 claims description 2
- 238000005299 abrasion Methods 0.000 claims description 2
- 238000012742 biochemical analysis Methods 0.000 claims description 2
- 231100000259 cardiotoxicity Toxicity 0.000 claims description 2
- 230000007681 cardiovascular toxicity Effects 0.000 claims description 2
- 230000008602 contraction Effects 0.000 claims description 2
- 239000007850 fluorescent dye Substances 0.000 claims description 2
- 238000003384 imaging method Methods 0.000 claims description 2
- 229910052751 metal Inorganic materials 0.000 claims description 2
- 239000002184 metal Substances 0.000 claims description 2
- 210000002894 multi-fate stem cell Anatomy 0.000 claims description 2
- 238000005096 rolling process Methods 0.000 claims description 2
- 210000001671 embryonic stem cell Anatomy 0.000 claims 1
- 238000000386 microscopy Methods 0.000 claims 1
- 235000013601 eggs Nutrition 0.000 description 129
- 239000007943 implant Substances 0.000 description 13
- 210000001519 tissue Anatomy 0.000 description 12
- 230000018109 developmental process Effects 0.000 description 11
- 210000002216 heart Anatomy 0.000 description 11
- 230000008569 process Effects 0.000 description 10
- 208000032843 Hemorrhage Diseases 0.000 description 8
- 230000000541 pulsatile effect Effects 0.000 description 8
- 238000002054 transplantation Methods 0.000 description 8
- 238000002474 experimental method Methods 0.000 description 6
- 210000001161 mammalian embryo Anatomy 0.000 description 6
- 230000008901 benefit Effects 0.000 description 5
- 210000004369 blood Anatomy 0.000 description 5
- 239000008280 blood Substances 0.000 description 5
- 230000000747 cardiac effect Effects 0.000 description 5
- 238000010438 heat treatment Methods 0.000 description 5
- 230000003902 lesion Effects 0.000 description 5
- 238000012360 testing method Methods 0.000 description 5
- 238000002604 ultrasonography Methods 0.000 description 5
- 238000005303 weighing Methods 0.000 description 5
- 241001465754 Metazoa Species 0.000 description 4
- 210000004413 cardiac myocyte Anatomy 0.000 description 4
- 210000000991 chicken egg Anatomy 0.000 description 4
- 230000006870 function Effects 0.000 description 4
- 238000004519 manufacturing process Methods 0.000 description 4
- 239000004793 Polystyrene Substances 0.000 description 3
- 238000010521 absorption reaction Methods 0.000 description 3
- 238000010171 animal model Methods 0.000 description 3
- 230000001413 cellular effect Effects 0.000 description 3
- 230000034994 death Effects 0.000 description 3
- 238000000338 in vitro Methods 0.000 description 3
- 238000001727 in vivo Methods 0.000 description 3
- 238000002347 injection Methods 0.000 description 3
- 239000007924 injection Substances 0.000 description 3
- 210000004379 membrane Anatomy 0.000 description 3
- 230000008520 organization Effects 0.000 description 3
- 230000007170 pathology Effects 0.000 description 3
- 229920002223 polystyrene Polymers 0.000 description 3
- 108090000623 proteins and genes Proteins 0.000 description 3
- 102000004169 proteins and genes Human genes 0.000 description 3
- 230000010349 pulsation Effects 0.000 description 3
- 230000000250 revascularization Effects 0.000 description 3
- 230000001225 therapeutic effect Effects 0.000 description 3
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 3
- 239000006144 Dulbecco’s modified Eagle's medium Substances 0.000 description 2
- HTTJABKRGRZYRN-UHFFFAOYSA-N Heparin Chemical compound OC1C(NC(=O)C)C(O)OC(COS(O)(=O)=O)C1OC1C(OS(O)(=O)=O)C(O)C(OC2C(C(OS(O)(=O)=O)C(OC3C(C(O)C(O)C(O3)C(O)=O)OS(O)(=O)=O)C(CO)O2)NS(O)(=O)=O)C(C(O)=O)O1 HTTJABKRGRZYRN-UHFFFAOYSA-N 0.000 description 2
- 241000272534 Struthio camelus Species 0.000 description 2
- 239000002390 adhesive tape Substances 0.000 description 2
- 230000008828 contractile function Effects 0.000 description 2
- 230000004069 differentiation Effects 0.000 description 2
- 239000003814 drug Substances 0.000 description 2
- 229940079593 drug Drugs 0.000 description 2
- 230000008144 egg development Effects 0.000 description 2
- 230000003203 everyday effect Effects 0.000 description 2
- 230000004720 fertilization Effects 0.000 description 2
- 239000011521 glass Substances 0.000 description 2
- 230000012010 growth Effects 0.000 description 2
- 210000002837 heart atrium Anatomy 0.000 description 2
- 229960002897 heparin Drugs 0.000 description 2
- 229920000669 heparin Polymers 0.000 description 2
- 230000002631 hypothermal effect Effects 0.000 description 2
- 230000007774 longterm Effects 0.000 description 2
- 230000000877 morphologic effect Effects 0.000 description 2
- 230000002062 proliferating effect Effects 0.000 description 2
- 230000008439 repair process Effects 0.000 description 2
- 239000000523 sample Substances 0.000 description 2
- 210000004881 tumor cell Anatomy 0.000 description 2
- 230000002792 vascular Effects 0.000 description 2
- 210000003462 vein Anatomy 0.000 description 2
- 206010003830 Automatism Diseases 0.000 description 1
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 1
- GHXZTYHSJHQHIJ-UHFFFAOYSA-N Chlorhexidine Chemical compound C=1C=C(Cl)C=CC=1NC(N)=NC(N)=NCCCCCCN=C(N)N=C(N)NC1=CC=C(Cl)C=C1 GHXZTYHSJHQHIJ-UHFFFAOYSA-N 0.000 description 1
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 1
- 206010061216 Infarction Diseases 0.000 description 1
- 206010029113 Neovascularisation Diseases 0.000 description 1
- 241000288906 Primates Species 0.000 description 1
- 206010039491 Sarcoma Diseases 0.000 description 1
- 208000007536 Thrombosis Diseases 0.000 description 1
- 238000009825 accumulation Methods 0.000 description 1
- 230000036982 action potential Effects 0.000 description 1
- 239000013543 active substance Substances 0.000 description 1
- 230000001154 acute effect Effects 0.000 description 1
- 239000011157 advanced composite material Substances 0.000 description 1
- 230000001772 anti-angiogenic effect Effects 0.000 description 1
- 230000002421 anti-septic effect Effects 0.000 description 1
- 230000004888 barrier function Effects 0.000 description 1
- 230000004071 biological effect Effects 0.000 description 1
- 238000001574 biopsy Methods 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 230000000740 bleeding effect Effects 0.000 description 1
- 210000004204 blood vessel Anatomy 0.000 description 1
- 229910052791 calcium Inorganic materials 0.000 description 1
- 239000011575 calcium Substances 0.000 description 1
- 238000004113 cell culture Methods 0.000 description 1
- 239000006285 cell suspension Substances 0.000 description 1
- 210000000038 chest Anatomy 0.000 description 1
- 229960003260 chlorhexidine Drugs 0.000 description 1
- 210000001136 chorion Anatomy 0.000 description 1
- 230000037020 contractile activity Effects 0.000 description 1
- 238000012258 culturing Methods 0.000 description 1
- 230000001419 dependent effect Effects 0.000 description 1
- 239000012153 distilled water Substances 0.000 description 1
- 210000003981 ectoderm Anatomy 0.000 description 1
- 210000001900 endoderm Anatomy 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 230000002255 enzymatic effect Effects 0.000 description 1
- 210000003743 erythrocyte Anatomy 0.000 description 1
- 210000002219 extraembryonic membrane Anatomy 0.000 description 1
- 230000002349 favourable effect Effects 0.000 description 1
- 239000003269 fluorescent indicator Substances 0.000 description 1
- 230000004927 fusion Effects 0.000 description 1
- 239000008103 glucose Substances 0.000 description 1
- 239000001963 growth medium Substances 0.000 description 1
- 235000015220 hamburgers Nutrition 0.000 description 1
- 230000002008 hemorrhagic effect Effects 0.000 description 1
- 210000005260 human cell Anatomy 0.000 description 1
- 230000007574 infarction Effects 0.000 description 1
- 208000028867 ischemia Diseases 0.000 description 1
- 238000002955 isolation Methods 0.000 description 1
- 238000009533 lab test Methods 0.000 description 1
- 238000013507 mapping Methods 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 239000002609 medium Substances 0.000 description 1
- 210000003716 mesoderm Anatomy 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000002107 myocardial effect Effects 0.000 description 1
- 210000004165 myocardium Anatomy 0.000 description 1
- 239000007908 nanoemulsion Substances 0.000 description 1
- 230000003287 optical effect Effects 0.000 description 1
- 210000000056 organ Anatomy 0.000 description 1
- 230000036542 oxidative stress Effects 0.000 description 1
- 230000001575 pathological effect Effects 0.000 description 1
- 210000003516 pericardium Anatomy 0.000 description 1
- 230000000144 pharmacologic effect Effects 0.000 description 1
- 230000001766 physiological effect Effects 0.000 description 1
- 235000013613 poultry product Nutrition 0.000 description 1
- 230000001737 promoting effect Effects 0.000 description 1
- 230000008929 regeneration Effects 0.000 description 1
- 238000011069 regeneration method Methods 0.000 description 1
- 210000000998 shell membrane Anatomy 0.000 description 1
- 230000019491 signal transduction Effects 0.000 description 1
- 239000000243 solution Substances 0.000 description 1
- 241000894007 species Species 0.000 description 1
- 230000004083 survival effect Effects 0.000 description 1
- 230000001360 synchronised effect Effects 0.000 description 1
- 238000002560 therapeutic procedure Methods 0.000 description 1
- 231100000331 toxic Toxicity 0.000 description 1
- 230000002588 toxic effect Effects 0.000 description 1
- 238000011282 treatment Methods 0.000 description 1
- 229960005486 vaccine Drugs 0.000 description 1
- 230000035899 viability Effects 0.000 description 1
- 230000000007 visual effect Effects 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/06—Animal cells or tissues; Human cells or tissues
- C12N5/0602—Vertebrate cells
- C12N5/0652—Cells of skeletal and connective tissues; Mesenchyme
- C12N5/0657—Cardiomyocytes; Heart cells
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
- A01K67/00—Rearing or breeding animals, not otherwise provided for; New or modified breeds of animals
- A01K67/027—New or modified breeds of vertebrates
- A01K67/0271—Chimeric vertebrates, e.g. comprising exogenous cells
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
- A01K2207/00—Modified animals
- A01K2207/12—Animals modified by administration of exogenous cells
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
- A01K2207/00—Modified animals
- A01K2207/15—Humanized animals
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
- A01K2227/00—Animals characterised by species
- A01K2227/30—Bird
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
- A01K2267/00—Animals characterised by purpose
- A01K2267/03—Animal model, e.g. for test or diseases
- A01K2267/035—Animal model for multifactorial diseases
- A01K2267/0375—Animal model for cardiovascular diseases
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2502/00—Coculture with; Conditioned medium produced by
- C12N2502/02—Coculture with; Conditioned medium produced by embryonic cells
- C12N2502/025—Coculture with; Conditioned medium produced by embryonic cells extra-embryonic cells, e.g. amniotic epithelium, placental cells, Wharton's jelly
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2502/00—Coculture with; Conditioned medium produced by
- C12N2502/28—Vascular endothelial cells
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2503/00—Use of cells in diagnostics
- C12N2503/02—Drug screening
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2533/00—Supports or coatings for cell culture, characterised by material
- C12N2533/90—Substrates of biological origin, e.g. extracellular matrix, decellularised tissue
- C12N2533/92—Amnion; Decellularised dermis or mucosa
Landscapes
- Life Sciences & Earth Sciences (AREA)
- Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Zoology (AREA)
- Biomedical Technology (AREA)
- Biotechnology (AREA)
- Chemical & Material Sciences (AREA)
- Cell Biology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Genetics & Genomics (AREA)
- Environmental Sciences (AREA)
- Wood Science & Technology (AREA)
- Organic Chemistry (AREA)
- Biochemistry (AREA)
- Rheumatology (AREA)
- General Engineering & Computer Science (AREA)
- General Health & Medical Sciences (AREA)
- Cardiology (AREA)
- Animal Behavior & Ethology (AREA)
- Animal Husbandry (AREA)
- Biodiversity & Conservation Biology (AREA)
- Microbiology (AREA)
- Materials For Medical Uses (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
Abstract
Description
Claims (10)
- REVENDICATIONS1. Procédé de greffe d'au moins une cellule cardiaque, ou d'au moins une cellule capable de se différentier en cellule cardiaque, ladite cellule étant choisie parmi : une cellule indifférenciée, une cellule totipotente, une cellule multipotente, une cellule souche, une cellule dite iPS, une cellule précurseur d'une cellule cardiaque et une cellule progénitrice d'une cellule cardiaque, à l'exception d'une cellule souche embryonnaire d'origine humaine, sur la membrane chorioallantoïde vascularisée d'un oeuf d'oiseau fécondé, ledit procédé comprenant la mise en oeuvre des étapes suivantes : - la culture en conditions ex ovo de l'oeuf fécondé, jusqu'à un stade de développement de l'oeuf d'au moins 8 jours, - la réalisation d'une microlésion en surface de la membrane chorioallantoïde (MCA) de l'oeuf fécondé, - la mise en contact d'au moins une cellule cardiaque, ou d'au moins une cellule capable de se différentier en cellules cardiaque, et de ladite MCA, au niveau de ladite microlésion, et - l'incubation de l'oeuf fécondé ainsi traité pendant au moins 48h dans une enceinte thermostatée, à une température comprise entre 36°C et 39°C et un degré d'hygrométrie compris entre 80% et 90%.
- 2. Procédé selon la revendication 1, caractérisé en ce que ladite cellule cardiaque est une cellule cardiaque isolée ou une cellule cardiaque d'un fragment de tissu cardiaque.
- 3. Procédé selon la revendication 1 ou 2, caractérisé en ce qu'il comprend les étapes suivantes : - la culture en conditions ex ovo de l'oeuf fécondé jusqu'à un stade de développement de l'oeuf d'au moins 9 jours, - la réalisation d'une microlésion en surface de la MCA de l'oeuf fécondé, - la mise en contact d'un fragment de tissu cardiaque et de ladite MCA au niveau de ladite microlésion, et - l'incubation de l'oeuf fécondé ainsi traité pendant au moins 48h dans une enceinte thermostatée, à une température comprise entre 36°C et 39°C et un degré d'hygrométrie compris entre 80% et 90%.
- 4. Procédé selon l'une des revendications 1 à 3, caractérisé en ce que la microlésion est réalisée par le retrait du feuillet ectodermique de l'oeuf fécondé, dans la zone d'implantation choisie. 3037338 18
- 5. Procédé selon l'une des revendications 1 à 4, dans lequel le feuillet ectodermique est retiré selon l'un des procédés suivants : - retrait à l'aide d'un papier souple capable d'épouser les irrégularités de la surface de la MCA, de préférence du papier buvard, 5 - retrait à l'aide d'un objet abrasif, de préférence capable de créer l'abrasion du feuillet ectodermique par grattage, ledit objet abrasif étant choisi de préférence parmi : une pointe d'aiguille métallique pour seringue et une pointe de cône pour pipette, - retrait à l'aide d'une substance absorbante, capable de coller à la surface de la MCA et de retirer par roulage le feuillet ectodermique, de préférence une pointe de coton tige. 10
- 6. Procédé selon l'une des revendications 1 à 5, caractérisé en ce que ladite cellule cardiaque ou ladite cellule capable de se différentier en cellule cardiaque provient d'un animal vertébré choisi parmi : les oiseaux, de préférence les poules, et les mammifères, de préférence les singes, les porcs, les souris, les rats et l'Homme 15
- 7. Procédé de caractérisation de l'activité d'un composé vis-à-vis du tissu cardiaque, ledit procédé comprenant les étapes suivantes : a) l'obtention d'un oeuf fécondé greffé avec du tissu cardiaque, obtenu par un procédé selon l'une des revendications 1 à 6, 20 b) l'injection du composé dans ledit oeuf fécondé greffé, de préférence par une injection intraveineuse, c) l'observation dudit tissu cardiaque, d) la comparaison des résultats de l'observation de l'étape c) avec les résultats de l'observation de tissu cardiaque d'un oeuf fécondé greffé avec du tissu cardiaque et n'ayant 25 pas reçu ledit composé, et e) la caractérisation de l'activité dudit composé.
- 8. Procédé selon la revendication 7, dans laquelle le tissu cardiaque est observé par une méthode d'observation choisie parmi : une méthode intra-vitale, de préférence écho Doppler et/ou 30 microscopie, des méthodes d'imagerie avec utilisation de sondes fluorescentes ou autre procédé permettant de mesurer la contraction et le rythme, et une méthode analytique invasive, de préférence une analyse histologique et/ou une analyse biochimique.
- 9. Utilisation d'un oeuf fécondé greffé, obtenu par un procédé selon l'une des revendications 1 à 6, pour caractériser la toxicité cardiaque d'un composé ou pour caractériser l'activité un composé vis-à-vis du tissu cardiaque. 3037338 19
- 10. Kit comprenant un oeuf fécondé greffé, obtenu par un procédé selon l'une des revendications 1 à6.
Priority Applications (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
FR1555364A FR3037338B1 (fr) | 2015-06-12 | 2015-06-12 | Procede de greffe de cellule cardiaque sur la membrane choriallantoide d'œuf feconde |
PCT/EP2016/063534 WO2016198699A1 (fr) | 2015-06-12 | 2016-06-13 | Procede de greffe de cellule cardiaque sur la membrane choriallantoide d'oeuf feconde |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
FR1555364A FR3037338B1 (fr) | 2015-06-12 | 2015-06-12 | Procede de greffe de cellule cardiaque sur la membrane choriallantoide d'œuf feconde |
FR1555364 | 2015-06-12 |
Publications (2)
Publication Number | Publication Date |
---|---|
FR3037338A1 true FR3037338A1 (fr) | 2016-12-16 |
FR3037338B1 FR3037338B1 (fr) | 2020-02-28 |
Family
ID=54478105
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
FR1555364A Expired - Fee Related FR3037338B1 (fr) | 2015-06-12 | 2015-06-12 | Procede de greffe de cellule cardiaque sur la membrane choriallantoide d'œuf feconde |
Country Status (2)
Country | Link |
---|---|
FR (1) | FR3037338B1 (fr) |
WO (1) | WO2016198699A1 (fr) |
Families Citing this family (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
FR3105260A1 (fr) | 2019-12-20 | 2021-06-25 | Centre National De La Recherche Scientifique (Cnrs) | Modèle organoïde cardiaque vascularisé apres incorporation de cardiomyocytes dérivés de cellules souches pluripotentes induites humaines |
Family Cites Families (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN101356270B (zh) | 2005-12-13 | 2014-02-12 | 国立大学法人京都大学 | 核重新编程因子 |
-
2015
- 2015-06-12 FR FR1555364A patent/FR3037338B1/fr not_active Expired - Fee Related
-
2016
- 2016-06-13 WO PCT/EP2016/063534 patent/WO2016198699A1/fr active Application Filing
Non-Patent Citations (8)
Title |
---|
DOMENICO R: "Chapter 5 : Chick Embryo Chorioallantoic Membrane as a Useful Tool to Study Angiogenesis", INTERNATIONAL REVIEW OF CELL AND MOLECULAR BIOLOGY, vol. 270, 2008, pages 181 - 224, XP008179854, ISSN: 1937-6448, DOI: 10.1016/S1937-6448(08)01405-6 * |
DUNN B E & BOONE M A: "Growth of the chick embryo in vitro", POULTRY SCIENCE, vol. 55, no. 3, May 1976 (1976-05-01), pages 1067 - 1071, XP008179857, ISSN: 0032-5791, DOI: 10.3382/PS.0551067 * |
KURODA Y & NAGATANI T: "Experimentally induced changes in fructose-1,6-diphosphatase activity in embryonic chick liver and heart cells in vitro", DEVELOPMENTAL BIOLOGY, vol. 11, no. 3, June 1965 (1965-06-01), pages 335 - 351, XP024787690, ISSN: 0012-1606, DOI: 10.1016/0012-1606(65)90043-6 * |
LATZIS R V & DRIZE N I: "Origin and localization of cells-blood precursors in the bird embryos: A study by means of xenogenic grafts on chorioallantois", ONTOGENEZ, vol. 11, no. 2, 1980, pages 203 - 208, XP008179867, ISSN: 0475-1450 * |
MURPHY J B & ROUS P: "The Behavior of Chicken Sarcoma Implanted in the Developing Embryo", THE JOURNAL OF EXPERIMENTAL MEDICINE, vol. 15, no. 2, February 1912 (1912-02-01), US, pages 119 - 132, XP055265973, ISSN: 0022-1007, DOI: 10.1084/jem.15.2.119 * |
RENAUD J-F & SPERELAKIS N: "Electrophysiological properties of chick embryonic hearts grafted and organ cultured in vitro", JOURNAL OF MOLECULAR AND CELLULAR CARDIOLOGY, vol. 8, no. 11, November 1976 (1976-11-01), pages 889 - 900, XP023000073, ISSN: 0022-2828, [retrieved on 20040204], DOI: 10.1016/0022-2828(76)90071-7 * |
SHOUGER R B ET AL: "Chorioallantoic grafts of embryonic chick hearts", TRANSPLANTATION BULLETIN, vol. 6, no. 2, April 1959 (1959-04-01), pages 417 - 420, XP008179864 * |
SOUTH M A ET AL: "Heart Grafts to Chorioallantoic Membranes of Chick embryos: Rejection by Adult Spleen Fragments", FEDERATION PROCEEDINGS, vol. 29, no. 2, 3291, 1970, pages 828, XP008179866, ISSN: 0014-9446 * |
Also Published As
Publication number | Publication date |
---|---|
FR3037338B1 (fr) | 2020-02-28 |
WO2016198699A1 (fr) | 2016-12-15 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
Sanchez et al. | Acellular human heart matrix: a critical step toward whole heart grafts | |
Ross et al. | Embryonic stem cells proliferate and differentiate when seeded into kidney scaffolds | |
JP6489484B2 (ja) | 自己組織化用細胞集合体の作製方法 | |
Baiguera et al. | Tissue engineered human tracheas for in vivo implantation | |
Haldi et al. | Human melanoma cells transplanted into zebrafish proliferate, migrate, produce melanin, form masses and stimulate angiogenesis in zebrafish | |
CN103458935B (zh) | 使组织或器官再细胞化以提高其可移植性的方法 | |
JP6011979B2 (ja) | 網膜色素上皮細胞シートの製造方法 | |
Proulx et al. | Tissue engineering of feline corneal endothelium using a devitalized human cornea as carrier | |
JP2016537414A (ja) | 心臓神経堤細胞、及びその使用方法 | |
JP6626245B2 (ja) | 再構成皮膚の作製用の組成物および方法 | |
JP5867926B2 (ja) | 細胞シート作製方法 | |
JP2023116525A (ja) | 網膜細胞への線維芽細胞の再プログラミング方法 | |
Toyoshima et al. | Regeneration of a bioengineered 3D integumentary organ system from iPS cells | |
JP2013540276A (ja) | 創傷を治癒するメタカリオート(metakaryotic)幹細胞、およびその使用方法 | |
JP2004533234A (ja) | カプセル化細胞インジケータシステム | |
FR3037338A1 (fr) | Procede de greffe de cellule cardiaque sur la membrane choriallantoide d'œuf feconde | |
Liu et al. | Enriched intestinal stem cell seeding improves the architecture of tissue-engineered intestine | |
WO2021123682A1 (fr) | Modèle organoïde cardiaque vascularisé apres incorporation de cardiomyocytes dérivés de cellules souches pluripotentes induites humaines | |
Liu et al. | Production of tissue-engineered small intestine in rats with different ages of cell donors | |
FR2891842A1 (fr) | Systemes et procedes de regeneration cellulaire et utilisations de telles cellules regenerees. | |
El‐Ghali et al. | New methods for chicken embryo manipulations | |
JP2023511003A (ja) | ヒト多能性幹細胞から調製された3dオルガノイドを分解することにより大量のオリゴデンドロサイトを確保するための分化方法 | |
CA3008553A1 (fr) | Modele d'etude animal du cancer | |
Kretschmar et al. | Methods for studying primary cilia in heart tissue after ischemia-reperfusion injury | |
Dong et al. | Development of coronary vessels |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PLFP | Fee payment |
Year of fee payment: 2 |
|
PLSC | Publication of the preliminary search report |
Effective date: 20161216 |
|
PLFP | Fee payment |
Year of fee payment: 3 |
|
TQ | Partial transmission of property |
Owner name: PHILIPPE NIRDE, FR Effective date: 20180330 Owner name: SYLVAIN RICHARD, FR Effective date: 20180330 Owner name: AMANDA FINAN-MARCHI, FR Effective date: 20180330 |
|
PLFP | Fee payment |
Year of fee payment: 4 |
|
PLFP | Fee payment |
Year of fee payment: 5 |
|
PLFP | Fee payment |
Year of fee payment: 6 |
|
ST | Notification of lapse |
Effective date: 20220205 |